UCB S.A. - Product Pipeline Review - 2016

  • ID: 3720479
  • Company Profile
  • 91 pages
  • Global Markets Direct
  • UCB (Union chimique belge)
1 of 4
UCB S.A. - Product Pipeline Review - 2016

Summary

‘UCB S.A. - Product Pipeline Review - 2016’, provides an overview of the UCB S.A.’s pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by UCB S.A., complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Our report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the pipeline therapeutic landscape of UCB S.A.
- The report provides overview of UCB S.A. including its business description, key facts, and locations and subsidiaries
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report assesses UCB S.A.’s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report features UCB S.A.’s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to buy

- Evaluate UCB S.A.’s strategic position with total access to detailed information on its product pipeline
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for UCB S.A.
- Identify potential new clients or partners in the target demographic
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding UCB S.A.’s pipeline depth and focus of pipeline therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
READ MORE
Note: Product cover images may vary from those shown
2 of 4
List of Tables

List of Figures

UCB S.A. Snapshot

UCB S.A. Overview

Key Information

Key Facts

UCB S.A. - Research and Development Overview

Key Therapeutic Areas

UCB S.A. - Pipeline Review

Pipeline Products by Stage of Development

Pipeline Products - Monotherapy

Pipeline Products - Partnered Products

Partnered Products/Combination Treatment Modalities

Pipeline Products - Out-Licensed Products

Out-Licensed Products/Combination Treatment Modalities

UCB S.A. - Pipeline Products Glance

UCB S.A. - Late Stage Pipeline Products

Pre-Registration Products/Combination Treatment Modalities

Phase III Products/Combination Treatment Modalities

UCB S.A. - Clinical Stage Pipeline Products

Phase II Products/Combination Treatment Modalities

Phase I Products/Combination Treatment Modalities

UCB S.A. - Early Stage Pipeline Products

Preclinical Products/Combination Treatment Modalities

Discovery Products/Combination Treatment Modalities

UCB S.A. - Drug Profiles

brivaracetam

Product Description

Mechanism of Action

R&D Progress

certolizumab pegol

Product Description

Mechanism of Action

R&D Progress

lacosamide

Product Description

Mechanism of Action

R&D Progress

levetiracetam

Product Description

Mechanism of Action

R&D Progress

rotigotine ER

Product Description

Mechanism of Action

R&D Progress

bimekizumab

Product Description

Mechanism of Action

R&D Progress

seletalisib

Product Description

Mechanism of Action

R&D Progress

UCB-0942

Product Description

Mechanism of Action

R&D Progress

UCB-7665

Product Description

Mechanism of Action

R&D Progress

dapirolizumab pegol

Product Description

Mechanism of Action

R&D Progress

UCB-4144

Product Description

Mechanism of Action

R&D Progress

UCB-6673

Product Description

Mechanism of Action

R&D Progress

Antibodies for Cancer, Immunology and Inflammation

Product Description

Mechanism of Action

R&D Progress

Monoclonal Antibody to Inhibit Fatty Acid-Binding Protein 4 for Diabetes and Metabolic Disorders

Product Description

Mechanism of Action

R&D Progress

Recombinant Protein to Inhibit TNF-Alpha for Alzheimer's Disease

Product Description

Mechanism of Action

R&D Progress

Antibody to Inhibit Transglutaminase 2 for Fibrosis

Product Description

Mechanism of Action

R&D Progress

Small Molecules to Inhibit Kinase for Neurodegenerative Diseases

Product Description

Mechanism of Action

R&D Progress

UCB S.A. - Pipeline Analysis

UCB S.A. - Pipeline Products by Target

UCB S.A. - Pipeline Products by Route of Administration

UCB S.A. - Pipeline Products by Molecule Type

UCB S.A. - Pipeline Products by Mechanism of Action

UCB S.A. - Recent Pipeline Updates

UCB S.A. - Dormant Projects

UCB S.A. - Discontinued Pipeline Products

Discontinued Pipeline Product Profiles

CDP-323

CDP-435

CDP-484

lacosamide

seletracetam

UCB-2892

UCB S.A. - Company Statement

UCB S.A. - Locations And Subsidiaries

Head Office

Other Locations & Subsidiaries

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

UCB S.A., Key Information

UCB S.A., Key Facts

UCB S.A. - Pipeline by Indication, 2016

UCB S.A. - Pipeline by Stage of Development, 2016

UCB S.A. - Monotherapy Products in Pipeline, 2016

UCB S.A. - Partnered Products in Pipeline, 2016

UCB S.A. - Partnered Products/ Combination Treatment Modalities, 2016

UCB S.A. - Out-Licensed Products in Pipeline, 2016

UCB S.A. - Out-Licensed Products/ Combination Treatment Modalities, 2016

UCB S.A. - Pre-Registration, 2016

UCB S.A. - Phase III, 2016

UCB S.A. - Phase II, 2016

UCB S.A. - Phase I, 2016

UCB S.A. - Preclinical, 2016

UCB S.A. - Discovery, 2016

UCB S.A. - Pipeline by Target, 2016

UCB S.A. - Pipeline by Route of Administration, 2016

UCB S.A. - Pipeline by Molecule Type, 2016

UCB S.A. - Pipeline Products by Mechanism of Action, 2016

UCB S.A. - Recent Pipeline Updates, 2016

UCB S.A. - Dormant Developmental Projects,2016

UCB S.A. - Discontinued Pipeline Products, 2016

UCB S.A., Subsidiaries

List of Figures

UCB S.A. - Pipeline by Top 10 Indication, 2016

UCB S.A. - Pipeline by Stage of Development, 2016

UCB S.A. - Monotherapy Products in Pipeline, 2016

UCB S.A. - Partnered Products in Pipeline, 2016

UCB S.A. - Out-Licensed Products in Pipeline, 2016

UCB S.A. - Pipeline by Top 10 Target, 2016

UCB S.A. - Pipeline by Route of Administration, 2016

UCB S.A. - Pipeline by Molecule Type, 2016

UCB S.A. - Pipeline Products by Top 10 Mechanism of Action, 2016
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
Note: Product cover images may vary from those shown
Adroll
adroll